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Prevalence and clinical correlates of
insomnia in adults with attention-deficit
hyperactivity disorder
Brevik EJ, Lundervold AJ, Halmøy A, Posserud MB, Instanes JT,
Bjorvatn B, Haavik J. Prevalence and clinical correlates of insomnia in
adults with attention-deficit hyperactivity disorder
Objective: To investigate the prevalence of insomnia in adults with
Attention-deficit hyperactivity disorder (ADHD) and its association
with clinical subtypes, current ADHD symptoms, and stimulant
treatment.
Method: We obtained diagnostic information, symptom rating scales
and treatment history from clinically ascertained adult ADHD patients
diagnosed according to DSM-IV criteria (n = 268, mean age 38.1 years)
and randomly selected population controls (n = 202, mean age
36.5 years). The Bergen Insomnia Scale (BIS) was used to measure
insomnia. ADHD symptom domains were self-rated using the Adult
ADHD Self-Rating Scale.
Results: Insomnia was far more frequent among adults with ADHD
(66.8%) than in the population controls (28.8%) (P < 0.001). Insomnia
was more common in adults with the combined subtype than in those
with the inattentive subtype (79.7% and 55.6%, respectively)
(P = 0.003). For self-reported current ADHD symptoms, inattention
was strongly correlated to insomnia. Patients currently using stimulant
treatment for ADHD reported a lower total insomnia score compared
to patients without medication (P < 0.05).
Conclusion: Insomnia was highly prevalent among adults with ADHD.
The lower insomnia score in patients on current stimulant treatment
suggests that stimulant treatment is not associated with worsening of
insomnia symptoms in adult ADHD patients.
E. J. Brevik1,2,3 ,
A. J. Lundervold2,3, A. Halmøy1,2,
M.-B. Posserud1,2,
J. T. Instanes2,4, B. Bjorvatn4,5,
J. Haavik1,2
1Division of Psychiatry, Haukeland University Hospital,
Bergen, 2K.G. Jebsen Centre for Neuropsychiatric
Disorders, Department of Biomedicine, University of
Bergen, Bergen, 3Department of Biological and Medical
Psychology, University of Bergen, Bergen, 4Department
of Global Public Health and Primary Care, University of
Bergen, Bergen, and 5Norwegian Competence Center
for Sleep Disorders, Haukeland University Hospital,
Bergen, Norway
This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and
is not used for commercial purposes.
Key words: attention-deficit hyperactivity disorder;
sleep; psychostimulants; clinical aspects;
neuropsychiatry
Erlend Joramo Brevik, Department of Biological and
Medical Psychology, University of Bergen, Postboks
7807, 5020 Bergen, Norway.
E-mail: erlendjb@gmail.com
Previous presentations
Poster presented at the 29th ECNP Congress, Vienna,
Austria, September 19–21, 2016. Oral presentations at
the 23rd ESRS Congress, Bologna, Italy, September 16,
2016; and the 4th NRSN PhD Research Conference,
Hurdalen, Norway, September 22, 2016.
Accepted for publication April 28, 2017
Significant Outcomes
• Insomnia is highly relevant in adult ADHD, with a fivefold increased risk compared with controls
• Stimulant treatment of ADHD in adults is not associated with worsening of insomnia, and may
potentially even be helpful in alleviating insomnia symptoms
• Insomnia was more common in the combined and hyperactive/impulsive subtypes than in the inatten-
tive subtype
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• Insomnia symptoms were based on self-reports, which may be unreliable and lead to an overestimation
• We do not include other sleep variables which may be of interest
• This study employed a cross-sectional, survey design, limiting the possibility of making causal conclu-
sions.
Introduction
Attention-deficit hyperactivity disorder (ADHD)
is a neurodevelopmental disorder characterized by
symptoms of inattention and/or hyperactivity/im-
pulsivity. Based on these symptom domains, the
Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV/DSM-5) differentiate between
inattentive (IA), hyperactive/impulsive (HI), and
combined subtypes/presentations (1). It is esti-
mated that 2–3% of the adult population suffer
from ADHD (2). People with ADHD typically
struggle with maintaining structure and regulating
their behaviour and daytime activities. The regula-
tory difficulties also seem to affect the diurnal
rhythm, as ADHD has been associated with vari-
ous sleep problems, with insomnia being one of the
most commonly reported comorbid conditions (3).
Insomnia is defined as difficulties initiating or
maintaining sleep, early morning awakenings or
having non-restorative sleep, lasting for at least a
month (1). Insomnia is one of the most frequent
health concerns in the general population as well
(4), typically affecting 6% to 15% of the adult pop-
ulation (5). Insomnia causes irritability and fatigue
as well as reduced productivity, increased absen-
teeism, increased morbidity, and increased health
care costs (4). Most studies examining the relation-
ship between insomnia and ADHD have been per-
formed in children and adolescents, and the few
studies addressing insomnia in adult ADHD have
given conflicting results (6, 7). One study found
that more than half of adults with probable
ADHD fulfilled the criteria for insomnia (8). In
another study, four of five adults with ADHD
reported having sleep problems, irrespective of sex
and subtype (9), indicating the importance of
addressing insomnia in adult ADHD.
It is well established that ADHD is associated
with impairment in cognitive functions such as
attention, vigilance and working memory, as well
as long-term memory, and decision-making (10).
Considering that insomnia also affects cognitive
functioning (9), insomnia in addition to ADHD
may lead to a vicious cycle where impairments are
exacerbated. Studies have shown that sleep prob-
lems in general are associated with inattention,
whereas some specific sleep problems have been
associated with the different ADHD subtypes (3).
According to Gau and Kessler (11), HI has been
associated with decreased sleep duration, whereas
IA has been associated with disturbed sleep,
delayed circadian rhythm, and greater sleep need
(8, 11–14). Meanwhile, the ADHD combined sub-
type is characterized by an overall higher symptom
burden and severity compared with the other sub-
types (15), which may also affect the rate of insom-
nia. Conversely, the severity of sleep problems is
associated with the severity levels of self-reported
ADHD symptoms, both among ADHD patients
and in the general population (11, 16, 17). Among
ADHD patients, this association held when
comorbidity and medication were taken into
account (17). Of the above cited studies, only three
studies (14, 16, 17) used samples with clinically
ascertained ADHD patients, the remaining used
questionnaires to assign ADHD status.
The relationship between sleep problems and
pharmacological treatment for adults with
ADHD is not settled. One study reported that
nearly four of five non-medicated ADHD partici-
pants suffered from sleep-onset insomnia (18),
while other studies have found insomnia to be a
side-effect of treatment with both stimulants (19)
and atomoxetine (20). There is, however, substan-
tial individual variation in whether these medica-
tions cause insomnia or not, and sleep problems
seem to decrease as the medication is titrated and
ADHD symptoms improve (21). Usually, insom-
nia as a side-effect of stimulant treatment attenu-
ates after 1–2 months treatment (22) and ADHD
patients on methylphenidate treatment have even
been found to self-report an improvement in sleep
quality (23).
Thus, although several studies on the relation-
ship between adult ADHD and insomnia have
been published, many of these are of modest qual-
ity, with few participants, unclear inclusion crite-
ria, and lack of validated diagnostic protocols.
Studies using large samples of clinically ascertained
adult ADHD patients and validated measures of
insomnia are therefore needed to clarify the rela-
tionship between insomnia, clinical subtypes, and
symptoms of ADHD and their relationship to
stimulant treatment (3).
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Aims of study
The aim of the current study was to determine the
prevalence of insomnia in a large Norwegian sam-
ple of adults with Attention-deficit hyperactivity
disorder (ADHD) compared with population con-
trols. Based on previous findings, we expected
adults with ADHD to experience higher levels of
insomnia than control subjects. We first compared
the prevalence of insomnia in the patient group
with the control group, then in subtypes of
ADHD, and in groups of patients on and off cur-
rent stimulant treatment. Finally, we calculated




This cross-sectional study is part of an ongoing
project on adults with ADHD in Norway
(http://www.uib.no/kgj-npd). The data included
in the present study were collected between 2011
and 2016. The sample included adult ADHD
patients (n = 268), clinically diagnosed by psychi-
atrists and psychologists according to the DSM-
IV criteria (1). All patients were born in Norway
of Norwegian parents. The first patients were
recruited from regional expert committees on
ADHD, subsequent patients were recruited from
clinical psychologists and psychiatrists in out-
patient clinics nationwide. Controls (n = 202)
were randomly selected and invited to participate
in the study directly from the Medical Birth
Registry of Norway. This registry includes all
persons born in Norway from January 1st 1967
(approx. 2.5 million persons at the time of
recruitment). To allow for comorbidities no for-
mal exclusion criteria were used in either sample.
This allowed for considerable comorbidities,
most noticeably in the adult ADHD group
(Table S1). All participants (n = 470) completed
a questionnaire including the six Bergen Insom-
nia Scale (BIS) items, the 18 item Adult ADHD
Self-Rating Scale (ASRS) and questions about
life-time comorbid disorders (e.g., have you ever
had severe anxiety and/or depression). For half
of the patients (n = 135/50.4%) clinician reported
information was available on the patients’
ADHD subtype and pharmacological treatment.
The ADHD subtypes were IA (n = 54), HI
(n = 6) or Combined (n = 75). As the HI group
was very small, the HI group was analyzed
together with the Combined group for ease of
interpretation. Pharmacological treatment data
included whether the patients were on (n = 94)
or off (n = 36) current pharmacological treat-
ment with methylphenidate (n = 69), amphetami-
nes (n = 12), atomoxetine (n = 3), or a
combination of these (n = 7). Three patients had
missing data on use of pharmacological treat-
ment. The patients on atomoxetine are included
in the group on current stimulant treatment in
this paper, as analyzing the data without these
patients did not alter the results. The differences
in distribution of sex and age between the
ADHD subtypes and between the stimulant
treatment groups were all non-significant. As no
interaction was found between medication use
and ADHD subtypes, we used the greatest sam-
ple sizes available when performing the respec-
tive analyses. All participants signed a written
informed consent, and the study was approved
by the Norwegian Regional Committee for Med-
ical and Health Research Ethics, RECWest (IRB
#3 (FWA00009490, IRB00001872)).
The Bergen Insomnia Scale
The Bergen Insomnia Scale (24) was constructed
based on the diagnostic criteria for insomnia
according to the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) (1). It includes six
items rated on an 8-point scale, ranging from 0 to
7 days per week during the last month. The first
four assess sleep impairment (criteria A of the
DSM-IV) (has it taken you more than 30 min to
fall asleep after the light was switched off; have
you been awake for more than 30 min between
periods of sleep; have you awakened more than
30 min earlier than you wished without managing
to fall asleep again; have you felt that you have not
had enough rest after waking up). The last two
items refer to daytime sleepiness/tiredness that has
affected your participation at school or work, and
your dissatisfaction with sleep respectively (criteria
B). The criteria for a DSM-IV diagnosis of insom-
nia are fulfilled if a respondent reports ≥3 days per
week on at least one of the A-items and ≥3 days
per week on at least one B item. In addition, a total
composite score is calculated by adding together
the scores for each item, with a possible range of
0–42. The BIS thus provides both a dichotomous
score for the presence of insomnia and a dimen-
sional symptom score. The Cronbach’s alpha of
the BIS scale used in the present study was 0.86.
The Adult ADHD Self-Rating Scale
The Adult ADHD Self-Rating Scale (ASRS) is the
World Health Organization’s (WHO) official
222
Brevik et al.
screener for ADHD, and consists of the 18 symp-
toms listed in the DSM-IV criteria A (25). Nine
items assess symptoms of inattention (ASRS-IA)
and nine items assess hyperactive/impulsive symp-
toms (ASRS-HI), respectively, rated on a scale
from 0 to 4 (0 = never, 1 = rarely, 2 = sometimes,
3 = often and 4 = very often), yielding a total
range of 0–72. The total scores on the two sub-
scales of IA and HI were used as continuous mea-
sures of the two main symptom domains of
ADHD. Cronbach’s alpha was 0.92 on the ASRS-
IA subscale and 0.92 on the ASRS-HI subscale.
Statistics and analytical plan
Data were analyzed using SPSS v-23 (26). Indepen-
dent samples t-tests were used to compare pairs of
groups on continuous variables and chi-square
tests for categorical variables. Logistic regression
analysis with insomnia (yes/no) as the output vari-
able was used to investigate the association
between self-reported current ADHD symptom
scores and the insomnia diagnosis. A final linear
regression model, with the BIS score as the output
variable, was included to investigate the associa-
tion between self-reported symptoms of inattention
and hyperactivity-impulsivity and the severity level
of insomnia symptoms. These two regression mod-
els were run separately for the ADHD and the con-
trol group. Adjusted models are controlled for age,
sex and self-reported comorbid anxiety/depression.
Significance levels were set at the 0.05 level on two-
tailed tests, unless otherwise indicated.
Results
The differences in mean age and sex distribution
between the ADHD patients and the controls were
non-significant (age range from 18 to 74 in the
ADHD sample and 19–73 in the controls, for more
details see Table 1). The BIS total sum score was
significantly higher in the ADHD group compared
to the control group (t (457.7) = 11.5, P <
0.001). In the clinician defined subgroups, the
Combined subtype had higher scores than the IA
subtype (t (131) = 2.1, P = 0.036). Furthermore,
ADHD patients currently using ADHD medica-
tion had lower insomnia scores than patients
without stimulant treatment (t (126) = 2.4, P =
0.017) (Table 2).
As shown in Table 2, the ADHD group had
higher scores on all six BIS items than the control
group. Overall, the prevalence of adults with
ADHD fulfilling the criteria for an insomnia diag-
nosis was 66.8%, which was significantly higher
than the prevalence of 28.8% in the control group
(v2 = 65.2, P < 0.001). The ADHD subtypes also
differed in prevalence of insomnia (v2 = 8.9,
P = 0.003), with the Combined subtype having a
higher prevalence of insomnia than the IA subtype
(79.7% and 55.6% respectively). There was no sig-
nificant difference in prevalence of insomnia
between the groups on and off stimulant treatment,
66.3% and 72.2% respectively) (Table 2). How-
ever, the treatment group reported a significantly
lower insomnia symptom score than the group not
currently on stimulant treatment.
As expected, the ADHD group had signifi-
cantly higher ASRS scores than the control
group (P < 0.001) (Table 3). Of note, the group
off medication reported higher ASRS scores than
the subgroup on current stimulant treatment on
both the ASRS-IA (t(87.4) = 3.7, P < 0.001) and
the ASRS-HI subscales (t(127) = 2.6, P = 0.011).
A logistic regression analysis showed that having
ADHD was associated with a five-fold increased
odds-ratio for insomnia in the full sample [OR:
5.0 (95% CI: 3.3–7.4)]. Further analyses included
the ASRS subscales as predictors (Table 4).
Logistic regression analysis showed that both
ASRS subscales were significantly associated
with insomnia in the full sample, but that only
ASRS-IA remained a significant predictor when
adjusting for sex, age and comorbid anxiety/de-
pression. Of note, the anxiety/depression variable
was dichotomous, whereas the ASRS consisted
of two scales. The odds of self-reported insom-
nia thus increased by 0.091 (OR = 1.091) per
increased score of ASRS-IA in the full sample.
When analyzed separately, anxiety/depression
was the only significant predictor of insomnia in
Table 1. Age and sex distributions in the control sample and the ADHD sample
Controls Total ADHD
ADHD Subtypes On current stimulant treatment









Age (SD) 36.5 (8.0) 38.1 (11.4) 33.2 (9.5) 35.9 (10.0) 34.1 (10.4) 36.7 (8.6)
Female (%) 62.9 59.7 70.4 55.6 66.0 63.9
SD, Standard deviation.
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the control sample, whereas ASRS-IA was the
only significant predictor in the ADHD sample.
The BIS sum score was included as an outcome
variable in a linear regression analysis (Table 5),
showing that 31% of its variance was explained by
the two ASRS-subscales in the full sample. Each
subscale contributed significantly, and they contin-
ued to do so even when controlled for sex, age and
comorbid anxiety/depression. When analyzed sep-
arately within the ADHD and control groups, sig-
nificant contribution was restricted to the ASRS-
HI subscale, with a somewhat stronger overall
explained variance in the ADHD group (16.1%)
than in the control group (9.7%). The ASRS-HI
scale remained significant in the adjusted models,
with sex and anxiety/depression as added
significant predictors in the control sample and
ASRS-IA and anxiety/depression as added signifi-
cant predictors in the ADHD sample.
Discussion
The present study showed that insomnia was far
more frequent among adults with ADHD (66.8%)
than in the population controls (28.8%), with the
highest prevalence in the Combined subtype
(79.7%). There was no significant difference in the
prevalence of insomnia between the ADHD sub-
groups on and off medication. The total BIS scores
of the un-medicated patients were, however, signif-
icantly higher than for patients receiving stimulant
treatment, as were the BIS scores of the Combined
compared to the IA subtype. Regression analyses
showed that the self-reported IA subscale of the
ASRS significantly contributed to explain an
insomnia diagnosis in the ADHD and the control
group, while both the ASRS-HI and ASRS-IA
subscales contributed significantly when the total
BIS score was used as an outcome variable.
Attention-deficit hyperactivity disorder and sleep
problems, including insomnia, are bi-directionally
related and mutually exacerbating conditions (9,
27). As ADHD is a heterogeneous developmental
disorder, there are likely to be variations in the rela-
tionship between ADHD and insomnia. We
explored this by examining differences in insomnia
for subtypes of ADHD as rated by the clinicians
referring the patients, and by including information
about self-reported ADHD symptoms. We found
that the ADHD Combined subtype had a higher
Table 2. Scores on the Bergen Insomnia Scale (BIS)














BIS1 Has it taken you more than 30 min to fall
asleep after the light was switched off?
1.4 (1.8) 3.4 (2.5)** 3.9 (2.4) 3.2 (2.6) 3.5 (2.5) 3.9 (2.4)
BIS2 Have you been awake for more than
30 min between periods of sleep?
1.0 (1.7) 2.2 (2.2)** 2.4 (2.4) 1.9 (2.1) 2.0 (2.2) 2.8 (2.3)
BIS3 Have you awakened more than 30 min
earlier than you wished without managing to fall asleep again?
0.8 (1.3) 2.2 (2.3)** 2.1 (2.5) 1.7 (1.9) 1.7 (2.1) 2.8 (2.4)*
BIS4 Have you felt that you have not had enough rest after waking up? 2.7 (2.0) 4.4 (2.3)** 4.9 (1.9) 4.0 (2.3)* 4.3 (2.1) 4.9 (2.3)
BIS5 Have you been so sleepy/tired that it has
affected you at school/work or in your private life?
1.0 (1.5) 2.5 (2.2)** 2.9 (2.1) 2.5 (2.1) 2.4 (2.0) 3.3 (2.1)*
BIS6 Have you been dissatisfied with your sleep? 1.9 (2.0) 3.7 (2.4)** 4.3 (2.1) 3.3 (2.4)* 3.6 (2.2) 4.5 (2.5)
BIS Sum (SD) 8.9 (7.4) 18.3 (10.1)** 20.6 (10.0) 16.8 (10.3)* 17.5 (9.5) 22.2 (10.6)*
BIS Insomnia (%) 28.8 66.8** 79.7 55.6** 66.3 72.2
*P < 0.05
**P < 0.01
Table 3. Scores on the Adult ADHD Self-Rating Scale (ASRS)
Controls Total ADHD
ADHD Subtypes On current stimulant treatment









ASRS SUM (SD) 21.5 (9.6) 42.7 (13.0)** 46.0 (12.0) 37.0 (13.9)** 40.2 (14.5) 47.8 (9.6)**
Inattention (SD) 11.8 (5.0) 22.5 (6.5)** 23.8 (6.2) 20.7 (7.5)** 21.1 (7.1) 25.4 (5.2)**





prevalence of insomnia than the IA subtype. When
including information about symptom domains,
reported at the same time as the insomnia symp-
toms, inattention was found to be most closely asso-
ciated with a diagnosis of insomnia. Since the
inattention score was substantially higher in the
ADHD-Combined subtype than the other subtypes
(see Table 3), both findings support the interpreta-
tion that overall ADHD severity is a main predictor
of insomnia. Our findings thus support previous
reports of the severity of sleep problems being
positively related to the severity of ADHD
symptoms (17).
The finding that inattentive symptoms were
more strongly correlated to insomnia symptoms
in the control group than in the ADHD group,
suggests that a close association between inatten-
tive symptoms and insomnia is not restricted to
adults with an ADHD diagnosis. Without any
information about causal relationship, inattentive
symptoms may as likely be a consequence of sleep
problems than the other way around. It is well
known that in itself, insomnia may mimic and
cause symptoms resembling ADHD and may also
exacerbate underlying ADHD symptoms (7), cre-
ating a vicious cycle. This may be detrimental to,
Table 4. Odds Ratios for Insomnia for the different ASRS ADHD symptom domains
Predictor Crude OR 95% CI P Adjusted OR 95% CI P
Full sample
Inattention 1.092 1.045–1.140 <0.001 1.091 1.043–1.141 <0.001
Hyperactivity/Impulsivity 1.050 1.008–1.093 0.019 1.036 0.994–1.080 0.095
Sex 0.697 0.453–1.072 0.100
Age 0.982 0.962–1.003 0.096
Anxiety/Depression 1.858 1.179–2.929 0.008
Controls
Inattention 1.095 1.007–1.191 0.035 1.087 0.995–1.188 0.065
Hyperactivity/Impulsivity 1.036 0.963–1.116 0.341 1.032 0.956–1.113 0.420
Sex 0.558 0.271–1.149 0.114
Age 0.984 0.945–1.025 0.443
Anxiety/Depression 2.504 1.098–5.711 0.029
ADHD
Inattention 1.062 1.005–1.123 0.034 1.068 1.009–1.131 0.022
Hyperactivity/Impulsivity 1.044 0.993–1.097 0.091 1.033 0.982–1.088 0.208
Sex 0.732 0.417–1.284 0.277
Age 0.983 0.960–1.008 0.179
Anxiety/Depression 1.324 0.738–2.374 0.346
OR, Odds ratio; CI, Confidence interval. Adjusted ORs have been controlled for age, sex, and comorbid anxiety/depression.
Table 5. Multiple Regression analyses for the effect of ASRS ADHD symptom domains on the BIS sum score
Predictor
Crude Adjusted
B SE B b P 95% CI for B B SE B b P 95% CI for B
Full sample
Inattention 0.327 0.084 0.255 <0.001 0.163–0.491 0.291 0.083 0.227 0.001 0.127–0.454
Hyperactivity/Impulsivity 0.406 0.079 0.334 <0.001 0.250–0.562 0.338 0.079 0.278 <0.001 0.183–0.492
Sex 1.704 0.796 0.082 0.033 0.140–3.268
Age 0.061 0.039 0.061 0.113 0.137–0.014
Anxiety/Depression 3.672 0.880 0.180 <0.001 5.401 to 1.943
Model F: 103.949 AdjR2 0.310 F: 49.207 AdjR2 0.345
Controls
Inattention 0.230 0.134 0.156 0.087 0.033 to 0.493 0.186 0.131 0.128 0.158 0.072 to 0.443
Hyperactivity/Impulsivity 0.265 0.120 0.201 0.028 0.029–0.501 0.238 0.114 0.185 0.038 0.014–0.463
Sex 2.065 1.000 0.138 0.040 0.094–4.037
Age 0.112 0.060 0.125 0.063 0.229 to 0.006
Anxiety/Depression 3.578 1.337 0.187 0.008 6.215 to 0.941
Model F: 11.572 AdjR2 0.097 F: 8.009 AdjR2 0.152
ADHD
Inattention 0.229 0.119 0.148 0.056 0.006 to 0.464 0.237 0.119 0.153 0.047 0.003–0.471
Hyperactivity/Impulsivity 0.411 0.107 0.295 <0.001 0.200–0.622 0.350 0.108 0.251 0.001 0.136–0.563
Sex 1.598 1.194 0.078 0.182 0.754 to 3.949
Age 0.036 0.051 0.040 0.480 0.136 to 0.064
Anxiety/Depression 2.923 1.242 0.137 0.019 5.368 to 0.478
Model F: 25.910 AdjR2 0.161 F: 12.246 AdjR2 0.178
B, Beta; SE, Standard Error; b, Standardized Beta; CI, Confidence interval; AdjR2, Adjusted R2. Adjusted models have been controlled for age, sex, and comorbid anxiety/depression.
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for example, learning outcomes, both through
lack of attentional resources and through lack of
consolidation through sleep (10). The bidirection-
ality of this relationship indicates that adequate
treatment of ADHD may also be important in
improving insomnia. One may be hesitant to use
stimulant medication late in the afternoon/evening
as insomnia has been associated with stimulant
treatment. Our findings however do not support
the advice to abstain from medication for fear of
causing or exacerbate insomnia in ADHD. The
prevalence of insomnia was so high that it should
rather be viewed as a problem intrinsic to ADHD.
Second, we found no support of an exacerbating
effect of stimulant treatment. In fact, and in line
with studies suggesting a beneficial effect of
ADHD medication in adults with ADHD (21,
23), we found that adult ADHD patients who
were currently on stimulant treatment obtained a
lower BIS sum score compared to those who were
not on stimulant treatment, although the preva-
lence of insomnia was similar across the two
groups. Generally, our findings fit well with and
extend previous studies on ADHD and insomnia
in children and adolescents (28, 29). According to
the present knowledge and the present study, the
best clinical practice seems to be active pharmaco-
logical management of ADHD, combined with a
close monitoring of sleep problems in all patients
with ADHD regardless of medication. The high
overall prevalence of insomnia in ADHD found
in the present study, and indications that ADHD
patients with the most severe symptoms are also
the ones with the most severe insomnia, make it
imperative to provide adequate treatment target-
ing insomnia in the clinical management of
ADHD, alongside other problems associated with
ADHD symptoms (30, 31). If insomnia is
detected, it should be specifically targeted in addi-
tion to the ADHD itself, but not preclude stimu-
lant treatment.
Limitations
This study employed a cross-sectional, survey
design, limiting the possibility of making causal
conclusions. Our definition of insomnia may be
inadequate to differentiate patients suffering from
delayed sleep phase disorder (DSPD), which is
not easily distinguishable from sleep-onset insom-
nia (32). The use of stimulant treatment was clin-
ician reported, not based on, for example, blood
samples, thus not objectively measured. Particu-
larly in the ADHD group, a large fraction of the
participants reported present and/or life-time
occurring comorbid conditions, such as anxiety/
depression, bipolar disorder, dyslexia or sub-
stance use disorders (Table S1) (33). While no
formal exclusion criteria were used to ensure
more clinically valid phenotypes, such comorbidi-
ties may have added to the general symptom
load, and also influenced the associations with
insomnia. The design of the present study pre-
cludes strong conclusions, as insomnia as a side-
effect from medication may be the cause for ces-
sation. Further studies with experimental designs
are needed to clarify this association. One way to
assess the relationship between sleep problems
and ADHD would be to systematically screen
for insomnia before starting stimulant treatment
of ADHD, thus enabling the clinical evaluation
of insomnia symptoms associated with stimulant
treatment (21).
Strengths of the study include the use of a large,
clinically validated sample of adult ADHD
patients and representative population controls, as
well as validated screening tools for insomnia and
ADHD symptoms. The BIS has high external and
internal validity and worked well in the present
study. Its brevity and free availability thus makes
it well suited to screen for and detect insomnia in
ADHD patients in clinical practice.
To conclude, insomnia is an important health
problem that needs to be addressed in adult
ADHD patients. Compared to population-based
controls, ADHD patients had a five-fold increased
odds ratio of having insomnia. Patients with the
Combined subtype of ADHD reported a signifi-
cantly higher prevalence of insomnia than the Inat-
tentive subtype. Patients currently using ADHD
medication reported significantly lower insomnia
scores than patients not using ADHD medication.
Our results indicate that stimulant treatment of
ADHD, as used in practice and over time, is not
associated with worsening of the severe difficulties
with insomnia that are found to be a commonly
associated condition of ADHD.
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